What diagnosis should be documented to obtain prior authorization for lidocaine 5% patches in a 60-year-old male?

Diagnosis for Lidocaine Patch Prior Authorization

For prior authorization of lidocaine 5% patches in a 60-year-old male, document postherpetic neuralgia (PHN) as the diagnosis, as this is the only FDA-licensed indication and the condition with strongest evidence for efficacy. 1, 2

Primary Indication

• Postherpetic neuralgia is the sole licensed indication for 5% lidocaine patches and has demonstrated efficacy in multiple randomized controlled trials with excellent tolerability 1, 2, 3
• The patches have shown significant pain reduction at all time points (30 minutes to 12 hours) compared to vehicle patches and no-treatment controls in PHN patients with allodynia 3
• First-line therapy status: Guidelines recommend topical lidocaine as a first-line medication for neuropathic pain, specifically PHN, with a maximum of 3 patches daily for 12-18 hours 1

Evidence Against Other Diagnoses

• Musculoskeletal pain should NOT be documented as it is explicitly not effective for this indication and represents inappropriate prescribing 4
• An audit found that 75-78% of lidocaine patch prescriptions were inappropriately written for musculoskeletal pain, with potential cost savings of €23,100-69,000 when this practice was stopped 4
• The patches have not proven effective for musculoskeletal or post-surgical pain despite widespread off-label use 4

Clinical Documentation Requirements

When documenting PHN for authorization, include:

• History of herpes zoster infection in the affected dermatome 2, 3
• Presence of allodynia on physical examination (tactile allodynia is a key feature that responds to lidocaine patches) 1, 3
• Chronic pain characteristics: continuous burning or intense paroxysmal pain persisting after acute herpes zoster resolution 2
• Duration of adequate trial: Plan for 3 weeks to assess efficacy 1

Alternative Neuropathic Pain Consideration

• Diabetic polyneuropathy (DPN) is a secondary consideration if the patient has documented diabetes with peripheral neuropathy, though this is off-label 5
• In comparative trials, lidocaine patches showed 65.3% response rates in mixed PHN/DPN populations, with fewer adverse events (3.9%) compared to pregabalin (39.2%) 5

Common Pitfall to Avoid

• Only 5-10% of patients prescribed lidocaine patches actually have PHN, meaning 90-95% of prescriptions nationally are inappropriate 4
• Insurance companies are increasingly scrutinizing these prescriptions due to high costs (€77-230 per month) and widespread inappropriate use 4